What question did this study set out to answer?

To assess the in vivo antitumor efficacy of conventional and novel chemotherapeutic agents against MIA PaCa-2 and PANC-1 human pancreatic carcinoma xenograft models.

January 1, 1993

Evaluation of new anticancer agents against the MIA PaCa-2 and PANC-1 human pancreatic carcinoma xenografts.

View Full Paper

Ask AI

Bookmark

Authors

RSRichard M. SchultzNorthwestern University RMRonald L. MerrimanPfizer (United States)JTJohn E. TothEli Lilly (United States)

Discussion

Member takes

Implication

Preclinical xenograft study demonstrates differential drug sensitivities in pancreatic carcinoma models, highlighting candidates for targeted therapy.

Key Points

To assess the in vivo antitumor efficacy of conventional and novel chemotherapeutic agents against MIA PaCa-2 and PANC-1 human pancreatic carcinoma xenograft models.
MIA PaCa-2 and PANC-1 tumors were maintained via serial trocar implantation in CD1 nu/nu mice.
Tested multiple anticancer agents (adriamycin, cisplatin, 5-fluorouracil, gemcitabine, diarylsulfonylureas, and taxol) at optimal schedules and maximum tolerated doses.
Adriamycin, cisplatin, and 5-fluorouracil were inactive (< 60% tumor weight inhibition), while gemcitabine demonstrated 69% inhibition in MIA PaCa-2 and 76% inhibition in PANC-1.
Diarylsulfonylureas (sulofenur and LY295501) yielded complete tumor inhibition in MIA PaCa-2 but were inactive in PANC-1.
Taxol achieved 80% tumor growth inhibition in PANC-1 but was completely inactive against MIA PaCa-2.

Cite This Study

Schultz et al. (1993) studied this question.

synapsesocial.com/papers/6a1bcd73d54006be995f0401 https://doi.org/10.1016/j.dld.2019.06.010

View Full Paper

Ask AI

Bookmark

Implication

Preclinical xenograft study demonstrates differential drug sensitivities in pancreatic carcinoma models, highlighting candidates for targeted therapy.

Evaluation of new anticancer agents against the MIA PaCa-2 and PANC-1 human pancreatic carcinoma xenografts.

Discussion

Member takes

Implication

Key Points

Cite This Study

Evaluation of new anticancer agents against the MIA PaCa-2 and PANC-1 human pancreatic carcinoma xenografts.

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider